PROLIA® TREATMENT IS ASSOCIATED WITH CONTINUOUS BMD INCREASE OVER 10 YEARS1,2
After 10 years of Prolia® treatment, improved BMD at the hip is associated with a lower incidence of non-vertebral fracture.1,3
In the FREEDOM extension, Prolia® continuously increased BMD at key skeletal sites over 10 years, including total hip, lumbar spine and femoral neck.1
Prolia® leads to rapid and profound decreases in bone turnover markers as early as 1 month. Sustained reductions in sCTx-1 and P1NP were observed over 10 years.1
Prolia® continuously increases hip BMD, whereas a therapeutic plateau is observed after 3-4 years of bisphosphonate therapy1,2
BMD: bone mineral density; P1NP: procollagen type 1 N-terminal propeptide; sCTx-1: serum C-terminal telopeptide of type 1 collagen.
- Bone HG, et al. Lancet Endocrinol Diabetes. 2017;5:513–23.
- Reid IR. Nat Rev Endocrinol. 2015;11:418–28.
- Ferrari S, et al. Osteoporos Int. 2016;27(Suppl 1): OC17.